Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 1, pp 17–24 | Cite as

The Impact of Education and Prescribing Guidelines on Opioid Prescribing for Breast and Melanoma Procedures

  • Jay S. Lee
  • Ryan A. Howard
  • Michael P. Klueh
  • Michael J. Englesbe
  • Jennifer F. Waljee
  • Chad M. Brummett
  • Michael S. Sabel
  • Lesly A. DossettEmail author
Health Services Research and Global Oncology

Abstract

Background

Excessive opioid prescribing is common in surgical oncology, with 72% of prescribed opioids going unused after curative-intent surgery. In this study, we sought to reduce opioid prescribing after breast and melanoma procedures by designing and implementing an intervention focused on education and prescribing guidelines, and then evaluating the impact of this intervention.

Methods

In this single-institution study, we designed and implemented an intervention targeting key factors identified in qualitative interviews. This included mandatory education for prescribers, evidence-based prescribing guidelines, and standardized patient instructions. After the intervention, interrupted time-series analysis was used to compare the mean quantity of opioid prescribed before and after the intervention (July 2016–September 2017). We also evaluated the frequency of opioid prescription refills.

Results

During the study, 847 patients underwent breast or melanoma procedures and received an opioid prescription. For mastectomy or wide local excision for melanoma, the mean quantity of opioid prescribed immediately decreased by 37% after the intervention (p = 0.03), equivalent to 13 tablets of oxycodone 5 mg. For lumpectomy or breast biopsy, the mean quantity of opioid prescribed decreased by 42%, or 12 tablets of oxycodone 5 mg (p = 0.07). Furthermore, opioid prescription refills did not significantly change for mastectomy/wide local excision (13% vs. 14%, p = 0.8), or lumpectomy/breast biopsy (4% vs. 5%, p = 0.7).

Conclusion

Education and prescribing guidelines reduced opioid prescribing for breast and melanoma procedures without increasing the need for refills. This suggests further reductions in opioid prescribing may be possible, and provides rationale for implementing similar interventions for other procedures and practice settings.

Notes

Funding

Dr. Lee is a National Research Service Award postdoctoral fellow supported by the National Cancer Institute (5T32 CA009672-23). Drs. Englesbe, Waljee, and Brummett receive funding from the Michigan Department of Health and Human Services and the National Institute on Drug Abuse (RO1 DA042859). The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Michigan Department of Health and Human Services.

Supplementary material

10434_2018_6772_MOESM1_ESM.tiff (25.8 mb)
Supplemental Fig. 1 Surgical Oncology Service Protocol for Postoperative Pain Medications. All prescribers in surgical oncology received a written protocol describing the new opioid prescribing guidelines and key points for patient education. The protocol also described strategies to optimize pain control while minimizing the need for opioids, such as infiltration of long-acting local anesthetic prior to incision. (TIFF 26451 kb)

References

  1. 1.
    Howard R, Waljee J, Brummett C, Englesbe M, Lee J. Reduction in opioid prescribing through evidence-based prescribing guidelines. JAMA Surg. 2018;153(3):285–287.CrossRefGoogle Scholar
  2. 2.
    Hill MV, McMahon ML, Stucke RS, Barth RJ Jr. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg. 2017;265(4):709–714.CrossRefGoogle Scholar
  3. 3.
    Feinberg AE, Chesney TR, Srikandarajah S, Acuna SA, McLeod RS, Best practice in surgery group. Opioid use after discharge in postoperative patients: a systematic review. Ann Surg. 2018;267(6):1056–1062.CrossRefGoogle Scholar
  4. 4.
    Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152(11):1066–1071.CrossRefGoogle Scholar
  5. 5.
    Maughan BC, Hersh EV, Shofer FS, et al. Unused opioid analgesics and drug disposal following outpatient dental surgery: a randomized controlled trial. Drug Alcohol Depend. 2016;168:328–334.CrossRefGoogle Scholar
  6. 6.
    Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS ONE. 2016;11(1):e0147972.CrossRefGoogle Scholar
  7. 7.
    Harris K, Curtis J, Larsen B, et al. Opioid pain medication use after dermatologic surgery a prospective observational study of 212 dermatologic surgery patients. JAMA Dermatol. 2013;149(3):317–321.CrossRefGoogle Scholar
  8. 8.
    Rodgers J, Cunningham K, Fitzgerald K, Finnerty E. Opioid consumption following outpatient upper extremity surgery. J Hand Surg Am. 2012;37(4):645–650.CrossRefGoogle Scholar
  9. 9.
    Bates C, Laciak R, Southwick A, Bishoff J. Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice. J Urol. 2011;185(2):551–555.CrossRefGoogle Scholar
  10. 10.
    Lee JS, Hu HM, Edelman AL, et al. New persistent opioid use among patients with cancer after curative-intent surgery. J Clin Oncol. 2017;35(36):4042–4049.CrossRefGoogle Scholar
  11. 11.
    Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504.CrossRefGoogle Scholar
  12. 12.
    Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain. 2016;157(6):1259–1265.CrossRefGoogle Scholar
  13. 13.
    Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An educational intervention decreases opioid prescribing after general surgical operations. Ann Surg. 2018;267(3):468–472.CrossRefGoogle Scholar
  14. 14.
    Dreyer T, Rontal R, Gabriel K, Udow-Phillips M. Uncoordinated prescription opioid use in Michigan. Ann Arbor, MI: Center for Healthcare Research and Transformation; Dec 2015. http://www.chrt.org/publication/uncoordinated-prescription-opioid-use-in-michigan/. Accessed 30 Mar 2018.
  15. 15.
    Fann JR, Ell K, Sharpe M. Integrating psychosocial care into cancer services. J Clin Oncol. 2012;30(11):1178–1186.CrossRefGoogle Scholar
  16. 16.
    Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–174.CrossRefGoogle Scholar
  17. 17.
    Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.CrossRefGoogle Scholar
  18. 18.
    Brummett CM, Janda AM, Schueller CM, et al. Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, observational cohort study. Anesthesiology. 2013;119(6):1434–1443.CrossRefGoogle Scholar
  19. 19.
    Janda AM, As-Sanie S, Rajala B, et al. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. Anesthesiology. 2015;122(5):1103–1111.CrossRefGoogle Scholar
  20. 20.
    Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18):1985–1992.CrossRefGoogle Scholar
  21. 21.
    Jung BF, Herrmann D, Griggs J, Oaklander AL, Dworkin RH. Neuropathic pain associated with non-surgical treatment of breast cancer. Pain. 2005;118(1–2):10–14.CrossRefGoogle Scholar
  22. 22.
    Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205–2211.CrossRefGoogle Scholar
  23. 23.
    Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699–2707.CrossRefGoogle Scholar
  24. 24.
    State and Federal Legislation Surrounding Initial Opioid Prescriptions. 2017. http://www.astho.org/StatePublicHealth/State-and-Federal-Legislation-Surrounding-Initial-Opioid-Prescriptions/03-08-18/. Accessed 22 Mar 2018.
  25. 25.
    Lee JS, Parashar V, Miller JB, et al. Opioid prescribing after curative-intent surgery: a qualitative study using the theoretical domains framework. Ann Surg Oncol. 2018;25(7):1843–1851.CrossRefGoogle Scholar
  26. 26.
    Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19(5):286–297.CrossRefGoogle Scholar
  27. 27.
    Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348–355.Google Scholar
  28. 28.
    Michigan Opioid Prescribing Engagement Network. Opioid prescribing recommendations for surgery. https://opioidprescribing.info/. Accessed 27 Mar 2018.
  29. 29.
    Sekhri S, Arora NS, Cottrell H, et al. Probability of opioid prescription refilling after surgery: does initial prescription dose matter? Ann Surg. 2018;268(2):271–276.CrossRefGoogle Scholar
  30. 30.
    Lee JS, Hu HM, Brummett CM, et al. Postoperative opioid prescribing and the pain scores on hospital consumer assessment of healthcare providers and systems survey. JAMA. 2017;317(19):2013–2015.CrossRefGoogle Scholar
  31. 31.
    Lipari RN, Hughes A. How people obtain the prescription pain relievers they misuse. The CBHSQ report. Rockville: Substance Abuse and Mental Health Administration; 2017. pp. 1–7.Google Scholar
  32. 32.
    Swenson CW, Kelley AS, Fenner DE, Berger MB. Outpatient narcotic use after minimally invasive urogynecologic surgery. Female Pelvic Med Reconstr Surg. 2016;22(5):377–381.CrossRefGoogle Scholar
  33. 33.
    Kim N, Matzon JL, Abboudi J, et al. A prospective evaluation of opioid utilization after upper-extremity surgical procedures: identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am. 2016;98(20):e89.CrossRefGoogle Scholar
  34. 34.
    Klueh MP, Hu HM, Howard RA, et al. Transitions of care for postoperative opioid prescribing in previously opioid-naïve patients in the USA: a retrospective review. J Gen Intern Med. Epub 11 Jun 2018.  https://doi.org/10.1007/s11606-018-4463-1.

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jay S. Lee
    • 1
    • 2
  • Ryan A. Howard
    • 1
  • Michael P. Klueh
    • 1
  • Michael J. Englesbe
    • 1
    • 2
  • Jennifer F. Waljee
    • 1
    • 2
  • Chad M. Brummett
    • 3
  • Michael S. Sabel
    • 1
  • Lesly A. Dossett
    • 1
    • 2
    • 4
    Email author
  1. 1.Department of SurgeryUniversity of Michigan Comprehensive Cancer CenterAnn ArborUSA
  2. 2.Center for Healthcare Outcomes and PolicyUniversity of MichiganAnn ArborUSA
  3. 3.Department of AnesthesiologyUniversity of MichiganAnn ArborUSA
  4. 4.Division of Surgical OncologyMichigan MedicineAnn ArborUSA

Personalised recommendations